open access

Vol 86, No 3 (2018)
REVIEWS
Published online: 2018-06-30
Submitted: 2018-02-28
Accepted: 2018-05-23
Get Citation

Immune checkpoint inhibitors in non-small cell lung cancer — towards daily practice

Joanna Domagała-Kulawik
DOI: 10.5603/ARM.2018.0022
·
Adv Respir Med 2018;86(3):142-148.

open access

Vol 86, No 3 (2018)
REVIEWS
Published online: 2018-06-30
Submitted: 2018-02-28
Accepted: 2018-05-23

Abstract

Immunotherapy with immune checkpoint inhibitors (ICIs) revolutionized therapy of solid tumors, among them- lung cancer. PD-1, PD-L1 blockers have been shown to improve overall survival in advanced, metastatic non-small cell lung cancer. In individual patients, 3-5-year survival has been achieved. Nivolumab, pembrolizumab, atezolizumab are approved in lung cancer treatment. Practical observations in reallife show that the results are comparable with those achieved in clinical trials. The effects of ICIs depend on the patient performance status; age, sex, histology; the presence of brain metastases have not modified treatment results. ICIs therapy is safe and well tolerated; immune related adverse events are observed. Pneumonitis may be a serious and fatal complication, but glucocorticoids are usually curative. For proper patients selection for ICIs treatment, the detection of PD-L1 expression on cancer cells is used. The so-called “hot” tumors with high expression of PD-L1 and abundant infiltration by cytotoxic cells seem to better respond to treatment than “cold” tumors.

Abstract

Immunotherapy with immune checkpoint inhibitors (ICIs) revolutionized therapy of solid tumors, among them- lung cancer. PD-1, PD-L1 blockers have been shown to improve overall survival in advanced, metastatic non-small cell lung cancer. In individual patients, 3-5-year survival has been achieved. Nivolumab, pembrolizumab, atezolizumab are approved in lung cancer treatment. Practical observations in reallife show that the results are comparable with those achieved in clinical trials. The effects of ICIs depend on the patient performance status; age, sex, histology; the presence of brain metastases have not modified treatment results. ICIs therapy is safe and well tolerated; immune related adverse events are observed. Pneumonitis may be a serious and fatal complication, but glucocorticoids are usually curative. For proper patients selection for ICIs treatment, the detection of PD-L1 expression on cancer cells is used. The so-called “hot” tumors with high expression of PD-L1 and abundant infiltration by cytotoxic cells seem to better respond to treatment than “cold” tumors.

Get Citation

Keywords

lung cancer, PD-1, PD-L1, immunotherapy, adverse events, immunoscoring

About this article
Title

Immune checkpoint inhibitors in non-small cell lung cancer — towards daily practice

Journal

Advances in Respiratory Medicine

Issue

Vol 86, No 3 (2018)

Pages

142-148

Published online

2018-06-30

DOI

10.5603/ARM.2018.0022

Bibliographic record

Adv Respir Med 2018;86(3):142-148.

Keywords

lung cancer
PD-1
PD-L1
immunotherapy
adverse events
immunoscoring

Authors

Joanna Domagała-Kulawik

References (36)
  1. Domagała-Kulawik J, Osińska I. [Immune alterations in lung cancer - the new therapeutic approach]. Pneumonol Alergol Pol. 2014; 82(3): 286–299.
  2. Travis WD, Brambilla E, Nicholson AG, et al. WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9): 1243–1260.
  3. Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017; 151(1): 193–203.
  4. Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9): 849–861.
  5. Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 2013; 73(8): 2381–2388.
  6. Domagala-Kulawik J, Osinska I, Hoser G. Mechanisms of immune response regulation in lung cancer. Transl Lung Cancer Res. 2014; 3(1): 15–22.
  7. Korczak-Kowalska G, Stelmaszczyk-Emmel A, Bocian K, et al. Expanding Diversity and Common Goal of Regulatory T and B Cells. II: In Allergy, Malignancy, and Transplantation. Arch Immunol Ther Exp (Warsz). 2017; 65(6): 523–535.
  8. Abril-Rodriguez G, Ribas A. SnapShot: Immune Checkpoint Inhibitors. Cancer Cell. 2017; 31(6): 848–848.e1.
  9. Costantini A, Grynovska M, Lucibello F, et al. Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. Eur Respir J. 2018; 51(2).
  10. Mascaux C, Tomasini P, Greillier L, et al. Personalised medicine for nonsmall cell lung cancer. Eur Respir Rev. 2017; 26(146).
  11. Kerr KM, Tsao MS, Nicholson AG, et al. IASLC Pathology Committee. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol. 2015; 10(7): 985–989.
  12. Reck M, Paz-Ares L. Immunologic checkpoint blockade in lung cancer. Semin Oncol. 2015; 42(3): 402–417.
  13. Dudnik E, Moskovitz M, Daher S, et al. Israel Lung Cancer Group. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. Lung Cancer. 2017 [Epub ahead of print].
  14. Molinier O, Besse B, Barlesi F, et al. IFCT 1502-CLINIVO : efficacité et tolérance du nivolumab et du traitement post-nivolumab dans le cancer bronchique non à petites cellules au stade avancé. Une étude en vie réelle dans le cadre de l’ATU nivolumab 2015. Revue des Maladies Respiratoires. 2018; 35: A8.
  15. Lee CK, Man J, Lord S, et al. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. J Thorac Oncol. 2017; 12(2): 403–407.
  16. Doubre H, Fraboulet S, Monnet I, et al. Réponse à l’immunothérapie des cancers bronchiques non à petites cellules (CBNPC) présentant des mutations induisant un épissage de l’exon 14 du gène MET  : à propos de 4 cas. Revue des Maladies Respiratoires. 2018; 35: A116–A117.
  17. Brahmer JR, Lacchetti C, Schneider BJ, et al. National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(17): 1714–1768.
  18. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018; 378(2): 158–168.
  19. Duchemann B, Didier M, Pailler MC, et al. Les inhibiteurs de PD1 et PDL1 peuvent-ils être utilisés sans risque dans la fibrose pulmonaire idiopathique ? Revue des Maladies Respiratoires. 2018; 35: A115–A116.
  20. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017; 35(7): 709–717.
  21. Reck M, Rodríguez-Abreu D, Robinson AG, et al. KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19): 1823–1833.
  22. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet. 2017; 389(10066): 255–265.
  23. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017; 12(2): 208–222.
  24. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014; 232(2): 199–209.
  25. Domagala-Kulawik J, Raniszewska A. How to evaluate the immune status of lung cancer patients before immunotherapy. Breathe (Sheff). 2017; 13(4): 291–296.
  26. Hoser G, Domagała-Kulawik J, Droszcz P, et al. Lymphocyte subsets differences in smokers and nonsmokers with primary lung cancer: a flow cytometry analysis of bronchoalveolar lavage fluid cells. Med Sci Monit. 2003; 9(8): BR310–BR315.
  27. Osińska I, Domagała-Kulawik J. [Bronchoalveolar lavage in lung cancer--diagnostic value and assessment of the anti-cancer immune response]. Postepy Hig Med Dosw (Online). 2013; 67: 1119–1127.
  28. Kwiecien I, Stelmaszczyk-Emmel A, Polubiec-Kownacka M, et al. Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans. Cancer Immunol Immunother. 2017; 66(2): 161–170.
  29. Osińska I, Stelmaszczyk-Emmel A, Polubiec-Kownacka M, et al. CD4+/CD25(high)/FoxP3+/CD127- regulatory T cells in bronchoalveolar lavage fluid of lung cancer patients. Hum Immunol. 2016; 77(10): 912–915.
  30. Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. 2018; 24(1): 47–53.
  31. Teng MWL, Ngiow SF, Ribas A, et al. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015; 75(11): 2139–2145.
  32. Yuan J, Hegde PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 2016; 4: 3.
  33. Galluzzi L, Senovilla L, Zitvogel L, et al. The secret ally: immunostimulation by anticancer drugs. Nature Reviews Drug Discovery. 2012; 11(3): 215–233.
  34. Domagała-Kulawik J. Immunomodulatory effect of stereotactic ablative radiotherapy in lung cancer. Pol Arch Intern Med. 2017; 127(4): 233–234.
  35. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017; 18(1): 31–41.
  36. Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013; 2013: 857519.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl